Flu Vaccine – Fall 2026

This study is an influenza vaccine compared with a licensed inactivated influenza vaccine for ages 65 and older.
Seasonal flu viruses are estimated by the World Health Organization to cause 3-5 million cases of severe illness and up to 650,000 deaths a year. Seasonal flu vaccine recommendations are designed to cover the strains of in flu determined to be the most prominent for the current flu season. The WHO (World Health Organization) recommends 3 strains to be used since one B-strain has not been prominent since 2020.
Improved vaccine immune response in adults age 50 and older is needed as the current licensed seasonal flu vaccines rarely exceed 60% effectiveness. Flu vaccines based on mRNA technology could provide several benefits in older adults compared with current vaccines including: the ability to respond to changes in the flu strain more quickly, avoid mutations that may be acquired in egg-based vaccine production, and exhibit a stronger immune response and protection.

You can contact our office at 501-623-9930 or fill out the short "Do You Qualify" Questionnaire to see if you qualify for this study.